Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More

Latest News

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

Learn More

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

Learn More

Coherus BioSciences Announces New Employment Inducement Grants

Learn More

Coherus issues white paper supporting “Securing America’s Medicines & Supply”

View Now